EUVIMEDEUVIMED entdecken
Crossref

Type 1 Diabetes Mellitus: Etiology, Pathogenesis, Diagnosis, Disease Staging, Prevention with Teplizumab, and Emerging Beta-Cell Replacement Therapies

Andre Manov

Journal of Medical Clinical Case Reports · 11.07.2026

DOI: 10.47485/2767-5416.1154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Clinical Case Reports, online erschienen am 11.07.2026. Verfasst von Andre Manov. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease marked by immune-mediated destruction of pancreatic β-cells, leading to absolute insulin deficiency. Historically, diagnosis occurred only after the onset of hyperglycemia and clinical symptoms. Advances in immunology and genetics have revealed presymptomatic stages of the disease, enabling earlier identification of individuals at risk. Teplizumab, an anti-CD3 monoclonal antibody, is the first disease-modifying therapy shown to delay progression to clinical diabetes. In parallel, stem cell-derived β-cell replacement therapies and islet transplantation are opening new possibilities for restoring endogenous insulin production. This article reviews the etiology, pathogenesis, diagnosis, staging, prevention strategies, and emerging curative approaches for T1DM.

Zitieren

APA

Manov, A. (2026). Type 1 Diabetes Mellitus: Etiology, Pathogenesis, Diagnosis, Disease Staging, Prevention with Teplizumab, and Emerging Beta-Cell Replacement Therapies. Journal of Medical Clinical Case Reports. https://doi.org/10.47485/2767-5416.1154

Vancouver

Manov A. Type 1 Diabetes Mellitus: Etiology, Pathogenesis, Diagnosis, Disease Staging, Prevention with Teplizumab, and Emerging Beta-Cell Replacement Therapies. Journal of Medical Clinical Case Reports. 2026. doi:10.47485/2767-5416.1154

BibTeX
@article{Manov2026,
  author = {Manov, Andre},
  title = {Type 1 Diabetes Mellitus: Etiology, Pathogenesis, Diagnosis, Disease Staging, Prevention with Teplizumab, and Emerging Beta-Cell Replacement Therapies},
  journal = {Journal of Medical Clinical Case Reports},
  year = {2026},
  doi = {10.47485/2767-5416.1154}
}
Kostenlos starten →